The purpose of this study is to obtain archived tumor tissue or pre-existing antigen
expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell
Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune
Medicines Treatment Protocol.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05061940.
This screening study is intended for men and women at least 18 years of age who have
selected advanced solid tumors. The study will assess the patient's selected tumor
antigens and/or HPV-16 E6/E7 expression profiles. Human leukocyte antigen (HLA) subtype
will also be assessed.
Based on the results, it will be determined if a patient is eligible to be considered for
a Repertoire Immune Medicines sponsored clinical trial(s) testing of the safety and
efficacy of a multi-antigen cytokine-enhanced T cell therapy. No treatment intervention
will occur as part of this screening study.
Upon enrollment, patients will be required to provide archival tumor tissue and saliva
samples. Based upon the results of these diagnostic analyses, if eligible, patients may
be enrolled in an appropriate interventional clinical trial(s) at the discretion of the
Investigator.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationRepertoire Immune Medicines
